<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23173" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hyperesthesia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Maldonado</surname>
            <given-names>Robert J.</given-names>
          </name>
          <aff>Georgetown University Hospital - National Rehabilitation Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>De Jesus</surname>
            <given-names>Orlando</given-names>
          </name>
          <aff>University of Puerto Rico, Medical Sciences Campus, Neurosurgery Section</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Robert Maldonado declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Orlando De Jesus declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>23</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23173.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Hyperesthesia occurs as a symptom of neuropathic pain and can be present in any disease process that affects the somatosensory nervous system. Treatment involves treating underlying conditions and symptomatic support. A multidisciplinary approach that is able to provide timely diagnosis and treatment has the best outcomes. This activity outlines the evaluation and management of hyperesthesia and reviews the role of the interprofessional team in evaluating and treating patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Summarize the etiology of hyperesthesia.</p></list-item><list-item><p>Identify which studies are appropriate to make a diagnosis of hyperesthesia.</p></list-item><list-item><p>Outline the treatment strategy for hyperesthesia/neuropathic pain.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23173&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23173">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23173.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The International Association for the Study of Pain defines hyperesthesia as &#x0201c;increased sensitivity to stimulation, excluding the special senses,&#x0201d; which &#x0201c;may refer to various modes of cutaneous sensibility including touch and thermal sensation without pain, as well as to pain.&#x0201d; While hyperesthesia can be used to describe any increased sensitivity to a stimulus, it is commonly used to describe a painful sensation from a stimulus.&#x000a0;</p>
        <p>Hyperesthesia is a common symptom of neuropathic pain. Neuropathic pain is defined by the International Association for the Study of Pain as &#x0201c;pain caused by a lesion or disease of the somatosensory system.&#x0201d; The neuropathic pain phenotype contains a spectrum of symptoms that can be roughly categorized into positive and negative symptoms. Hyperesthesia is a positive symptom of neuropathic pain. Positive symptoms are categorized as stimulus-dependent pain, stimulus-independent pain, and paresthesias.<xref ref-type="bibr" rid="article-23173.r1">[1]</xref> Neuropathic pain affects about 7-8% of the general population.<xref ref-type="bibr" rid="article-23173.r2">[2]</xref><xref ref-type="bibr" rid="article-23173.r3">[3]</xref></p>
        <p>In this article, hyperesthesia will be defined as an increased cutaneous sensitivity manifesting as stimulus-dependent neuropathic pain. The most common hyperesthesias are allodynia and hyperalgesia. Allodynia is a pain caused by a stimulus that usually does not elicit a painful response (i.e., pain on light touch). Hyperalgesia is an exaggerated pain response to a stimulus that usually causes pain (i.e., out of proportion pain from a pinprick). While most neuropathic pain symptoms are contained within the dermatomal distribution of the affected nerve, hyperesthesia has been known to extend beyond the affected nerve&#x02019;s distribution. This can sometimes obscure the correct diagnosis and lead to the inappropriate diagnosis of a psychosomatic disorder.<xref ref-type="bibr" rid="article-23173.r4">[4]</xref></p>
        <p>A detailed history and a thorough physical examination should be sufficient to identify the underlying etiology. Routine laboratories should be ordered as part of the workup. Special laboratory, diagnostic, and imaging tests may have to be ordered to make a definitive diagnosis of the etiology. Treatable and reversible etiologies should be promptly treated. The mainstay of treatment is symptomatic relief via pharmacological, non-pharmacological, and interventional therapies. Symptoms are typically challenging to eliminate, and patients will most likely continue to experience persistent symptoms. A multidisciplinary team approach has been shown to provide the most effective and lasting results.</p>
      </sec>
      <sec id="article-23173.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Neuropathic pain symptoms, including hyperesthesia, develop secondarily to a disease or a lesion of the nervous system that results in abnormal functioning of the somatosensory system. The etiology of hyperesthesia can be categorized anatomically or etiologically. Anatomically speaking, the source can be either central or peripheral.</p>
        <p>
<bold>Peripheral</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Systemic disease: diabetes mellitus (DM), nutritional deficiency, hypothyroidism, vasculitis, sarcoidosis, carcinoma/paraneoplastic, Guillain-Barre syndrome/acute inflammatory demyelinating polyneuropathy, chronic demyelinating inflammatory neuropathies, monoclonal gammopathy (amyloidosis, multiple myeloma, plasmacytoma, monoclonal gammopathy of undetermined significance), porphyria, Sjogren&#x02019;s syndrome, and critical illness.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Infectious: human immunodeficiency viruses (HIV), human T-cell lymphotropic virus, herpes simplex virus, varicella-zoster virus, Ebstein-Barr virus, West Nile virus, hepatitis C virus, rabies virus, cytomegalovirus, diphtheria,&#x000a0;Campylobacter jejuni, Mycobacterium tuberculosis, Mycobacterium leprae, Brucella spp., Clostridium botulinum, and Borrelia burgdorferi.<xref ref-type="bibr" rid="article-23173.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Toxic:&#x000a0;</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Drugs: isoniazid, chemotherapeutics (vinca-alkaloids, taxanes, platinum compounds), statins, amiodarone, antimicrobials (isoniazid, linezolid, and metronidazole), and immunosuppressants (tumor necrosis factor inhibitors, leflunomide, and nucleoside analog reverse-transcriptase inhibitors).<xref ref-type="bibr" rid="article-23173.r6">[6]</xref></p>
              </list-item>
              <list-item>
                <p>Other toxins: ethanol and heavy metals</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Mechanical: trauma, compressive mononeuropathies, complex regional pain syndrome type, post-amputation pain/phantom limb pain, trigeminal neuralgia, post-mastectomy pain syndrome, failed back surgery syndrome, and radiculopathies (nerve root compression)</p>
          </list-item>
          <list-item>
            <p>Hereditary: Charcot-Marie-Tooth disease and metachromatic leukodystrophy</p>
          </list-item>
        </list>
        <p>
<bold>Central</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Systemic disease: B12 myelopathy, multiple sclerosis, spinal cord stroke, brain stroke/central post-stroke pain syndrome(CPSP), opioid-induced hyperalgesia, and infectious (Herpes simplex virus, myelitis, encephalitis)</p>
          </list-item>
          <list-item>
            <p>Mechanical: spinal cord injury, tumor compression (brain and spinal cord), syringomyelia, and myelopathy<xref ref-type="bibr" rid="article-23173.r1">[1]</xref><xref ref-type="bibr" rid="article-23173.r7">[7]</xref><xref ref-type="bibr" rid="article-23173.r8">[8]</xref><xref ref-type="bibr" rid="article-23173.r9">[9]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23173.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Epidemiological studies of hyperesthesia are technically challenging to perform. Barriers to performing accurate epidemiological studies include the vast amount of conditions that can cause hyperesthesia and the subjective nature of hyperesthesia. Two epidemiological studies that focused on the prevalence of chronic pain with neuropathic pain features estimated the prevalence of neuropathic pain among the general population to be 7 to 8%.<xref ref-type="bibr" rid="article-23173.r2">[2]</xref><xref ref-type="bibr" rid="article-23173.r3">[3]</xref></p>
        <p>One study that used a questionnaire to assess sensory symptoms in patients with painful diabetic neuropathy (PDN) and postherpetic neuralgia (PHN) found that allodynia was present in about 50% of the PHN patients. That study contained 1600 patients with PDN, of which 18% reported pain to light touch, and 14% reported occasional pain with heat or cold.<xref ref-type="bibr" rid="article-23173.r10">[10]</xref> Another study performed quantitative sensory testing of 1236 patients with diagnosed neuropathic pain. The study used both mechanical and thermal stimuli. Their results showed that 20% of patients had brush-provoked allodynia. The study also found that mechanical hyperalgesias (pinprick 29% and blunt pressure 36%) occurred more often than thermal hyperalgesias (hot 24% and cold 19%).<xref ref-type="bibr" rid="article-23173.r11">[11]</xref></p>
      </sec>
      <sec id="article-23173.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathophysiology of neuropathic pain has been extensively studied, and several important mechanisms have been identified. Some of the identified mechanisms provide clear explanations for the development of hyperesthesias.<xref ref-type="bibr" rid="article-23173.r7">[7]</xref>&#x000a0;The mechanisms that lead to the development of hyperesthesia are central sensitization of the somatosensory system, peripheral sensitization of the somatosensory system, and dysfunction of endogenous pain inhibition. It is believed that mechanical hyperesthesia(e.g., light pinprick and light manual pressure) and mechanical allodynia (i.e., stroking the skin with a brush) are due to the sensitization of the somatosensory system (i.e., peripheral sensitization and central sensitization) and dysfunction of endogenous pain inhibition.<xref ref-type="bibr" rid="article-23173.r12">[12]</xref>&#x000a0;Cold hyperesthesias are believed to be due to either peripheral sensitization or central disinhibition. Heat hyperesthesias are believed to be due to peripheral sensitization of nerve fibers.<xref ref-type="bibr" rid="article-23173.r13">[13]</xref></p>
        <list list-type="order">
          <list-item>
            <p>Central sensitization is defined as an increase in the synaptic efficacy and excitability of nociceptive pathways in the central nervous system (CNS). Through this mechanism, pain signals entering the CNS are amplified. The process by which the central sensitization of the somatosensory system occurs is not well understood. One proposed mechanism suggests that A-beta touch cells undergo phenotypic changes, which then express increased levels of neuropeptides and increased activity of amino acid transmission.<xref ref-type="bibr" rid="article-23173.r12">[12]</xref><xref ref-type="bibr" rid="article-23173.r13">[13]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Peripheral sensitization most often occurs after peripheral nerve inflammation and leads to a reduced threshold for activation and hyperexcitability of primary afferent neurons. This is believed to occur due to post-translational changes, trafficking, and expression of the&#x000a0;transient receptor potential cation channel subfamily V member 1 (TRPV1) that arise after nerve damage. After these changes, peripheral nerves are more sensitive to mechanical and thermal stimuli.<xref ref-type="bibr" rid="article-23173.r13">[13]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Dysfunction of endogenous pain inhibition&#x000a0;most likely occurs due to reduced GABA and glycine inhibition of second-order neurons leading to a net excitation of these neurons.<xref ref-type="bibr" rid="article-23173.r14">[14]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23173.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>
<bold>History</bold>
</p>
        <p>A thorough history should be performed, as this should be sufficient to make a diagnosis of hyperesthesia.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Past medical history (diabetes mellitus, stroke, fractures, irritable bowel syndrome)</p>
          </list-item>
          <list-item>
            <p>Psychiatric history (mood disorders)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Medications (use of neurotoxic drugs)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Surgery&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Family history&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Sexual history</p>
          </list-item>
          <list-item>
            <p>Substance use (alcohol or opioid)</p>
          </list-item>
          <list-item>
            <p>Functional history: A functional history that examines the effect of the patient&#x02019;s symptoms on their ability to function should be performed. It should focus on any impairments to the patient&#x02019;s activities of daily living, instrumental activities of daily living, ambulatory status (use of assistive devices), work, or sleep.<xref ref-type="bibr" rid="article-23173.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>History of presenting illness: The examiner should gather a thorough description of the patient&#x02019;s pain symptoms. The description of the patient&#x02019;s symptoms should include all of the following components.
<list list-type="bullet"><list-item><p>Location&#x000a0;</p></list-item><list-item><p>Intensity (0-10 rating scale)&#x000a0;</p></list-item><list-item><p>Quality (burning, cold, hot, or allodynia) Pain descriptors such as burning, tingling, or shooting are the most characteristic of neuropathic pain syndrome and have a high likelihood of being present along with hyperesthesia.<xref ref-type="bibr" rid="article-23173.r7">[7]</xref></p></list-item><list-item><p>Onset (did the symptoms occur after an inciting event)</p></list-item><list-item><p>Temporal variation: At what time of the day is the pain worse? (neuropathic pain tends to be worse towards the end of the day) Has the pain progressively worsened over some time?&#x000a0;</p></list-item><list-item><p>Radiation (does the pain have axial origin)</p></list-item><list-item><p>Positional variation (i.e., is the pain worse in the lower back or the thigh)</p></list-item><list-item><p>Aggravating/alleviating factors</p></list-item><list-item><p>Attempted treatments (neuropathic pain symptoms are typically non-responsive to acetaminophen or nonsteroidal anti-inflammatory drugs)&#x000a0;</p></list-item><list-item><p>Frequency&#x000a0;</p></list-item><list-item><p>Associated symptoms (loss of range of motion, skin or hair changes, muscle spasms, muscle weakness, changes in sensation, redness, or swelling)&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Physical Exam</bold>
</p>
        <p>A complete neurological exam should be performed in addition to a general focused physical exam.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Cranial nerve testing (CNS lesions may have cranial nerve involvement)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Manual motor testing (weakness may be present in both peripheral and central etiologies, and any weakness should be differentiated as either real weakness or antalgic weakness)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Deep tendon reflexes (may be brisk in central etiologies and diminished in peripheral etiologies)</p>
          </list-item>
          <list-item>
            <p>Sensory testing</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Light touch (allodynia)</p>
              </list-item>
              <list-item>
                <p>Pinprick (hyperalgesia)&#x000a0;</p>
              </list-item>
              <list-item>
                <p>Vibration and&#x000a0; proprioception&#x000a0;</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Temperature (ice and hot packs for possible thermal allodynia)</p>
          </list-item>
          <list-item>
            <p>Straight leg test or slump test (radiculopathy)</p>
          </list-item>
          <list-item>
            <p>Tinel&#x02019;s sign (peripheral nerve entrapment)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Myofascial trigger points&#x000a0;</p>
          </list-item>
          <list-item>
            <p>For complex regional pain syndrome (CRPS), a skin examination should be performed focusing on cutaneous temperature discrepancies, color changes, hidrosis, scars in a dermatomal distribution, and hair changes.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23173.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The first step should be to determine whether the etiology is peripheral&#x000a0;or central.&#x000a0;It is essential to accurately diagnose the cause of hyperesthesia to provide treatment for any treatable underlying cause.</p>
        <p>
<bold>Laboratory Tests</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Routine: Should be considered as part of a standard workup of peripheral hyperesthesia</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Complete blood count</p>
              </list-item>
              <list-item>
                <p>Comprehensive metabolic panel</p>
              </list-item>
              <list-item>
                <p>Fasting blood glucose</p>
              </list-item>
              <list-item>
                <p>Erythrocyte sedimentation rate</p>
              </list-item>
              <list-item>
                <p>Thyroids stimulating hormone</p>
              </list-item>
              <list-item>
                <p>Vitamine B12</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>If indicated, based on clinical suspicion:</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Hemoglobin A1c (HbA1c)</p>
              </list-item>
              <list-item>
                <p>HIV antibodies</p>
              </list-item>
              <list-item>
                <p>Liver panel</p>
              </list-item>
              <list-item>
                <p>Lyme&#x000a0;antibodies</p>
              </list-item>
              <list-item>
                <p>Rapid plasma reagin (RPR), venereal disease research laboratory (VDRL)</p>
              </list-item>
              <list-item>
                <p>Urinalysis</p>
              </list-item>
              <list-item>
                <p>Urine protein electrophoresis</p>
              </list-item>
              <list-item>
                <p>Serum protein electrophoresis</p>
              </list-item>
              <list-item>
                <p>Angiotensin-converting enzyme levels</p>
              </list-item>
              <list-item>
                <p>Antinuclear antibody (ANA) test</p>
              </list-item>
              <list-item>
                <p>Perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) test</p>
              </list-item>
              <list-item>
                <p>Antineutrophil cytoplasmic antibodies (C-ANCA) test</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Tests for rare conditions</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Paraneoplastic panel</p>
              </list-item>
              <list-item>
                <p>Antimyelin associated glycoprotein</p>
              </list-item>
              <list-item>
                <p>Antiganglioside antibodies</p>
              </list-item>
              <list-item>
                <p>Salivary flow rate</p>
              </list-item>
              <list-item>
                <p>Cerebrospinal fluid analysis</p>
              </list-item>
              <list-item>
                <p>Genetic testing</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p><bold>Imaging:</bold> imaging is typically not needed to diagnose hyperesthesia, but it helps diagnose specific conditions.</p>
        <list list-type="bullet">
          <list-item>
            <p>Computed tomographic scan and magnetic resonance imaging (nerve root compression, herniated disc, myelopathy, tumor in the brain or spinal cord)</p>
          </list-item>
          <list-item>
            <p>Triple-phase bone scan (can be used to support a diagnosis of CRPS)<xref ref-type="bibr" rid="article-23173.r7">[7]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Special Tests:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Electrodiagnostics: electromyography and nerve conduction studies (only tests large fibers)</p>
          </list-item>
          <list-item>
            <p>Punch skin biopsy (identifies small-fiber neuropathy)<xref ref-type="bibr" rid="article-23173.r7">[7]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23173.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment of hyperesthesia and other neuropathic pain symptoms is challenging but is best achieved by using a multidisciplinary team approach that can focus on treating underlying causes, administering pharmacotherapy, applying interventional therapy, addressing functional impairments, and providing mental health services if needed.<xref ref-type="bibr" rid="article-23173.r7">[7]</xref><xref ref-type="bibr" rid="article-23173.r9">[9]</xref>&#x000a0;Realistic goals for&#x000a0;hyperesthesia should be established early on. Any comorbidities, such as mood disorders or sleep disturbances, should be addressed promptly. Patients typically require close follow-up to monitor response to therapy and continued evaluation of the underlying cause.</p>
        <p>For peripheral neuropathy, the most common treatable causes are diabetes mellitus, hypothyroidism, and nutritional deficiencies.<xref ref-type="bibr" rid="article-23173.r8">[8]</xref> Other causes of hyperesthesia, such as nerve root compression or peripheral nerve entrapment, may be initially treated conservatively with symptomatic pharmacotherapeutic support, physical therapy, lifestyle modifications, and minimally invasive procedures (i.e., epidural steroid injection or peripheral nerve injection). However, if there is worsening or stagnation of function, surgery may be required.</p>
        <p>Pharmacological treatments can be used to treat both central and peripheral causes of hyperesthesia. Of the pharmacological options available, antidepressants and antiepileptic drugs are the most widely used.<xref ref-type="bibr" rid="article-23173.r15">[15]</xref>&#x000a0;General guidelines for treatment are provided below; however, recommendations for the treatment of choice for specific etiologies are provided.</p>
        <p><bold>First-line drugs:</bold> These drugs have the most substantial evidence to support their treatment of neuropathic pain symptoms. This group contains two classes of&#x000a0;antidepressants and one class of antiepileptic drugs.</p>
        <list list-type="bullet">
          <list-item>
            <p>Antidepressants: all medications in this class have the added benefit of treating comorbid mood disorders.</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>TCAs: amitriptyline, imipramine, and nortriptyline</p>
              </list-item>
              <list-item>
                <list list-type="bullet">
                  <list-item>
                    <p>Indications:&#x000a0;painful diabetic neuropathy (PDN), postherpetic neuralgia<italic toggle="yes">&#x000a0;</italic>(PHN), central poststroke pain (CPSP)</p>
                  </list-item>
                </list>
              </list-item>
              <list-item>
                <p>SNRIs: duloxetine and venlafaxine</p>
              </list-item>
              <list-item>
                <list list-type="bullet">
                  <list-item>
                    <p>Indications: PDN, post-traumatic neuropathic pain, CRPS, radiculopathy, and central pain</p>
                  </list-item>
                </list>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Antiepileptic drugs:</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Gabapentinoids: Gabapentin and pregabalin</p>
              </list-item>
              <list-item>
                <list list-type="bullet">
                  <list-item>
                    <p>Indications: PDN, PHN, central pain, posttraumatic neuropathic pain, CRPS, radiculopathy. Pregabalin has proven to be effective in the treatment of&#x000a0;spinal cord injury central pain.<xref ref-type="bibr" rid="article-23173.r16">[16]</xref><xref ref-type="bibr" rid="article-23173.r17">[17]</xref></p>
                  </list-item>
                </list>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>
<bold>Second-line treatments:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Topicals</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Lidocaine 5% patch</p>
              </list-item>
              <list-item>
                <p>Capsaicin 8% patch: should ideally be applied by specially trained healthcare providers, as it requires pretreatment with topical lidocaine. May require postprocedural analgesics for 7-10 days. Relief may last up to 3 months.&#x000a0;</p>
              </list-item>
              <list-item>
                <list list-type="bullet">
                  <list-item>
                    <p>Indications: PHN and HIV-associated neuropathy</p>
                  </list-item>
                </list>
              </list-item>
            </list>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Analgesic</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Tramadol: Nonspecific analgesic, Mu-opioid receptor agonist but also blocks serotonin and norepinephrine reuptake.</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p><bold>Third-line treatments:</bold>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Strong Opioids</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Indications: Phantom pain, CRPS, central pain, PHN, and PDN</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Botulinum toxin-A</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Indications: PHN</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>Not all patients will respond to monotherapy; in fact, 45% of individuals with neuropathic pain are on two or more medications for their pain. If a patient fails first-line monotherapy, they can be used in combination (i.e., gabapentinoid + TCA or SNRI).<xref ref-type="bibr" rid="article-23173.r18">[18]</xref></p>
        <p>
<bold>Interventional Therapies:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Epidural steroid injections: considered third-line therapy.</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Indications: Radiculopathies<xref ref-type="bibr" rid="article-23173.r19">[19]</xref><xref ref-type="bibr" rid="article-23173.r20">[20]</xref></p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Sympathetic nerve block</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Indications: CRPS patients who have failed other treatments.<xref ref-type="bibr" rid="article-23173.r21">[21]</xref></p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Neurostimulation: Fourth-line treatment<xref ref-type="bibr" rid="article-23173.r18">[18]</xref></p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Spinal cord stimulation:</p>
              </list-item>
              <list-item>
                <list list-type="bullet">
                  <list-item>
                    <p>Indications: CRPS and failed back surgery syndrome (FBSS)<xref ref-type="bibr" rid="article-23173.r22">[22]</xref></p>
                  </list-item>
                </list>
              </list-item>
              <list-item>
                <p>Motor cortex stimulation:</p>
              </list-item>
              <list-item>
                <list list-type="bullet">
                  <list-item>
                    <p>Indication: CPSP and facial pain</p>
                  </list-item>
                </list>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Transcutaneous electrical nerve stimulation (TENS)</p>
          </list-item>
        </list>
        <p>Some interventional treatments currently being practiced lack robust trials to be recommended by the guidelines. Some of the interventions that require continued research are radiofrequency denervation of the dorsal root ganglion, adhesiolysis for FBSS, TENS, spinal cord stimulation, and motor cortex stimulation.</p>
      </sec>
      <sec id="article-23173.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Nociceptive source of pain</p>
          </list-item>
          <list-item>
            <p>Myofascial pain syndrome</p>
          </list-item>
          <list-item>
            <p>Fibromyalgia</p>
          </list-item>
          <list-item>
            <p>Chronic fatigue syndrome</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23173.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>It is difficult to completely eliminate hyperesthesias and other neuropathic pain symptoms. This should be explained to the patient early during the treatment course. Monotherapy should be initially started; however,&#x000a0;45% of the patients with neuropathic pain are on two or more medications for their pain.</p>
      </sec>
      <sec id="article-23173.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of&#x000a0;hyperesthesia include increased morbidity if symptoms are not controlled. The patient may also experience increased morbidity from extensive interventional procedures. Also, if the patient is started on potent opioids for treatment, the patient may become addicted.</p>
      </sec>
      <sec id="article-23173.s12" sec-type="Consultations">
        <title>Consultations</title>
        <p>Consultations with the following may be required:</p>
        <list list-type="bullet">
          <list-item>
            <p>Pain medicine specialist</p>
          </list-item>
          <list-item>
            <p>Sleep medicine professionals</p>
          </list-item>
          <list-item>
            <p>Physical therapy</p>
          </list-item>
          <list-item>
            <p>Occupational therapy</p>
          </list-item>
          <list-item>
            <p>Psychiatrist</p>
          </list-item>
          <list-item>
            <p>Psychologist</p>
          </list-item>
          <list-item>
            <p>Neurologist</p>
          </list-item>
          <list-item>
            <p>Neurosurgeon</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23173.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Here are important points to take note of:</p>
        <list list-type="bullet">
          <list-item>
            <p>Managing the patient's expectations is crucial in the treatment plan. Hyperesthesia and other neuropathic pain symptoms are difficult to control, and complete resolution will most likely never be achieved. It is essential to discuss this with the patient early on during the treatment course.</p>
          </list-item>
          <list-item>
            <p>Hyperesthesia and other neuropathic pain symptoms are best managed with an interdisciplinary team. This provides the best possible pain control and has the best outcomes.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Treatment should proceed in a stepwise manner.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Interventional procedures should be offered to patients who are not adequately managed with pharmacotherapy or wish to wean off high-risk medications such as opioids.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>It is vital to manage comorbid conditions, such as mood disorders and sleeping difficulties.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The current treatment plan and possible treatments should be discussed with the patient regularly.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23173.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Early identification of hyperesthesia and other neuropathic pain symptoms is essential to start the patient on a proper treatment plan. The education of the patient early on during the treatment is necessary to establish realistic pain goals. Always treat with a multidisciplinary team approach.&#x000a0;While the general practitioner is almost always involved in the care of patients with hyperesthesia, it is essential to consult with an interprofessional team of specialists that includes pain medicine specialists, sleep medicine professionals, physical therapists, and occupational therapists. A psychiatrist and psychologist evaluations are recommended as many patients suffer from mood disorders.</p>
      </sec>
      <sec id="article-23173.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23173&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23173">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/pain-management/hyperesthesia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=23173">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23173/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23173">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23173.s16">
        <title>References</title>
        <ref id="article-23173.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gilron</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Baron</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Neuropathic pain: principles of diagnosis and treatment.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>90</volume>
            <issue>4</issue>
            <fpage>532</fpage>
            <page-range>532-45</page-range>
            <pub-id pub-id-type="pmid">25841257</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23173.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bouhassira</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lant&#x000e9;ri-Minet</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Attal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Laurent</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Touboul</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of chronic pain with neuropathic characteristics in the general population.</article-title>
            <source>Pain</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>136</volume>
            <issue>3</issue>
            <fpage>380</fpage>
            <page-range>380-387</page-range>
            <pub-id pub-id-type="pmid">17888574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23173.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torrance</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey.</article-title>
            <source>J Pain</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>281</fpage>
            <page-range>281-9</page-range>
            <pub-id pub-id-type="pmid">16618472</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23173.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gilron</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Cahill</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Moulin</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Neuropathic pain: a practical guide for the clinician.</article-title>
            <source>CMAJ</source>
            <year>2006</year>
            <month>Aug</month>
            <day>01</day>
            <volume>175</volume>
            <issue>3</issue>
            <fpage>265</fpage>
            <page-range>265-75</page-range>
            <pub-id pub-id-type="pmid">16880448</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23173.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brizzi</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Lyons</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Peripheral nervous system manifestations of infectious diseases.</article-title>
            <source>Neurohospitalist</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>230</fpage>
            <page-range>230-40</page-range>
            <pub-id pub-id-type="pmid">25360209</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23173.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vilholm</surname>
                <given-names>OJ</given-names>
              </name>
              <name>
                <surname>Christensen</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Zedan</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Itani</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced peripheral neuropathy.</article-title>
            <source>Basic Clin Pharmacol Toxicol</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>115</volume>
            <issue>2</issue>
            <fpage>185</fpage>
            <page-range>185-92</page-range>
            <pub-id pub-id-type="pmid">24786912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23173.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Watson</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Dyck</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Peripheral Neuropathy: A Practical Approach to Diagnosis and Symptom Management.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>90</volume>
            <issue>7</issue>
            <fpage>940</fpage>
            <page-range>940-51</page-range>
            <pub-id pub-id-type="pmid">26141332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23173.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Azhary</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Farooq</surname>
                <given-names>MU</given-names>
              </name>
              <name>
                <surname>Bhanushali</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Majid</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kassab</surname>
                <given-names>MY</given-names>
              </name>
            </person-group>
            <article-title>Peripheral neuropathy: differential diagnosis and management.</article-title>
            <source>Am Fam Physician</source>
            <year>2010</year>
            <month>Apr</month>
            <day>01</day>
            <volume>81</volume>
            <issue>7</issue>
            <fpage>887</fpage>
            <page-range>887-92</page-range>
            <pub-id pub-id-type="pmid">20353146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23173.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zilliox</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Neuropathic Pain.</article-title>
            <source>Continuum (Minneap Minn)</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>23</volume>
            <issue>2, Selected Topics in Outpatient Neurology</issue>
            <fpage>512</fpage>
            <page-range>512-532</page-range>
            <pub-id pub-id-type="pmid">28375916</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23173.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baron</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>T&#x000f6;lle</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Gockel</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Brosz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Freynhagen</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>A cross-sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: Differences in demographic data and sensory symptoms.</article-title>
            <source>Pain</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>146</volume>
            <issue>1-2</issue>
            <fpage>34</fpage>
            <page-range>34-40</page-range>
            <pub-id pub-id-type="pmid">19592166</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23173.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Wasner</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Saddier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Baron</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient.</article-title>
            <source>Drugs Aging</source>
            <year>2008</year>
            <volume>25</volume>
            <issue>12</issue>
            <fpage>991</fpage>
            <page-range>991-1006</page-range>
            <pub-id pub-id-type="pmid">19021299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23173.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gierthm&#x000fc;hlen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Baron</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Neuropathic Pain.</article-title>
            <source>Semin Neurol</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>36</volume>
            <issue>5</issue>
            <fpage>462</fpage>
            <page-range>462-468</page-range>
            <pub-id pub-id-type="pmid">27704502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23173.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>von Hehn</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Baron</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Woolf</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Deconstructing the neuropathic pain phenotype to reveal neural mechanisms.</article-title>
            <source>Neuron</source>
            <year>2012</year>
            <month>Feb</month>
            <day>23</day>
            <volume>73</volume>
            <issue>4</issue>
            <fpage>638</fpage>
            <page-range>638-52</page-range>
            <pub-id pub-id-type="pmid">22365541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23173.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jensen</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Finnerup</surname>
                <given-names>NB</given-names>
              </name>
            </person-group>
            <article-title>Allodynia and hyperalgesia in neuropathic pain: clinical manifestations and mechanisms.</article-title>
            <source>Lancet Neurol</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>13</volume>
            <issue>9</issue>
            <fpage>924</fpage>
            <page-range>924-35</page-range>
            <pub-id pub-id-type="pmid">25142459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23173.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Finnerup</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Attal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Haroutounian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McNicol</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Baron</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dworkin</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Gilron</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Haanp&#x000e4;&#x000e4;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hansson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Kamerman</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Lund</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Raja</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Rice</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Rowbotham</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sena</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Siddall</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis.</article-title>
            <source>Lancet Neurol</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>162</fpage>
            <page-range>162-73</page-range>
            <pub-id pub-id-type="pmid">25575710</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23173.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siddall</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Cousins</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Otte</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Griesing</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chambers</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>TK</given-names>
              </name>
            </person-group>
            <article-title>Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial.</article-title>
            <source>Neurology</source>
            <year>2006</year>
            <month>Nov</month>
            <day>28</day>
            <volume>67</volume>
            <issue>10</issue>
            <fpage>1792</fpage>
            <page-range>1792-800</page-range>
            <pub-id pub-id-type="pmid">17130411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23173.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cardenas</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Nieshoff</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Suda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Goto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sanin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kaneko</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sporn</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Parsons</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Soulsby</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Whalen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Scavone</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Knapp</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>A randomized trial of pregabalin in patients with neuropathic pain due to spinal cord injury.</article-title>
            <source>Neurology</source>
            <year>2013</year>
            <month>Feb</month>
            <day>05</day>
            <volume>80</volume>
            <issue>6</issue>
            <fpage>533</fpage>
            <page-range>533-9</page-range>
            <pub-id pub-id-type="pmid">23345639</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23173.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bates</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schultheis</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Hanes</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Jolly</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Chakravarthy</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Deer</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>A Comprehensive Algorithm for Management of Neuropathic Pain.</article-title>
            <source>Pain Med</source>
            <year>2019</year>
            <month>Jun</month>
            <day>01</day>
            <volume>20</volume>
            <issue>Suppl 1</issue>
            <fpage>S2</fpage>
            <page-range>S2-S12</page-range>
            <pub-id pub-id-type="pmid">31152178</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23173.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chou</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Loeser</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Owens</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Rosenquist</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Atlas</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Baisden</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Carragee</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Grabois</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Resnick</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Stanos</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Shaffer</surname>
                <given-names>WO</given-names>
              </name>
              <name>
                <surname>Wall</surname>
                <given-names>EM</given-names>
              </name>
              <collab>American Pain Society Low Back Pain Guideline Panel</collab>
            </person-group>
            <article-title>Interventional therapies, surgery, and interdisciplinary rehabilitation for low back pain: an evidence-based clinical practice guideline from the American Pain Society.</article-title>
            <source>Spine (Phila Pa 1976)</source>
            <year>2009</year>
            <month>May</month>
            <day>01</day>
            <volume>34</volume>
            <issue>10</issue>
            <fpage>1066</fpage>
            <page-range>1066-77</page-range>
            <pub-id pub-id-type="pmid">19363457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23173.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manchikanti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Abdi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Atluri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Benyamin</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Boswell</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Buenaventura</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Bryce</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Burks</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Caraway</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Calodney</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Cash</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Christo</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Colson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Conn</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cordner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Coubarous</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Datta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Deer</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Diwan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Falco</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Fellows</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Geffert</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grider</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hameed</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hameed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Helm</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Janata</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Justiz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Manchikanti</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>McManus</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Onyewu</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Parr</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>VB</given-names>
              </name>
              <name>
                <surname>Racz</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Sehgal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Simopoulos</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Snook</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Swicegood</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Vallejo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Wargo</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hirsch</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>An update of comprehensive evidence-based guidelines for interventional techniques in chronic spinal pain. Part II: guidance and recommendations.</article-title>
            <source>Pain Physician</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>16</volume>
            <issue>2 Suppl</issue>
            <fpage>S49</fpage>
            <page-range>S49-283</page-range>
            <pub-id pub-id-type="pmid">23615883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23173.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dworkin</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>O'Connor</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Kent</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mackey</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Raja</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Stacey</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Backonja</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baron</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Harke</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Loeser</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Treede</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Turk</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Interventional management of neuropathic pain: NeuPSIG recommendations.</article-title>
            <source>Pain</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>154</volume>
            <issue>11</issue>
            <fpage>2249</fpage>
            <page-range>2249-2261</page-range>
            <pub-id pub-id-type="pmid">23748119</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23173.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cruccu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Aziz</surname>
                <given-names>TZ</given-names>
              </name>
              <name>
                <surname>Garcia-Larrea</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hansson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Lefaucheur</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>EFNS guidelines on neurostimulation therapy for neuropathic pain.</article-title>
            <source>Eur J Neurol</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>14</volume>
            <issue>9</issue>
            <fpage>952</fpage>
            <page-range>952-70</page-range>
            <pub-id pub-id-type="pmid">17718686</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
